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ABSTRACT
Objectives: Effective oral therapies for hepatitis B and
C have recently been developed, while there are no
approved pharmacological therapies for alcoholic and
non-alcoholic fatty liver diseases (ALD and NAFLD).
We hypothesise that fewer advances in fatty liver
diseases could be related to disparities in research
attention.
Methods: We developed the Attention-to-Burden
Index (ABI) that compares the research activities
during 2010–2014, and an estimate of disease burden
of these 4 major liver diseases. The resulting ratio
reflects either overattention (positive value) or
inadequate attention (negative value) compared with
disease burden. The mean research attention and
disease burden were calculated from 5 and 6 different
parameters, respectively. The efficacy rate of current
pharmacological therapies was assessed from
published clinical trials.
Findings: The mean research attention for hepatitis B
and C was 31% and 47%, respectively, while NAFLD
and ALD received 17% and 5%. The overall burden
was 5% and 28% for hepatitis B and C, and 17% and
50% for NAFLD and ALD. The calculated ABI for
hepatitis B and C revealed a +6.7-fold and +1.7-fold
overattention, respectively. NAFLD received an
appropriate attention compared with its burden, while
ALD received marked inadequate attention of −9.7-
fold. The efficacy rate of current pharmacological
agents was 72% for hepatitis B, 89% for hepatitis C,
25% for non-alcoholic steatohepatitis and 13% for
alcoholic hepatitis. Importantly, we found a positive
correlation between the mean attention and the efficacy
rate of current therapies in these 4 major liver
diseases.
Interpretation: There are important disparities
between research attention and disease burden among
the major liver diseases. While viral hepatitis has
received considerable attention, there is a marked
inadequate attention to ALD. There is a critical need to
increase awareness of ALD in the liver research
community.
INTRODUCTION
Liver diseases are a major cause of morbidity
and mortality.1 The main causes include
chronic viral hepatitis B (HBV) and C
(HCV), as well as alcoholic and non-
alcoholic fatty liver diseases (ALD and
NAFLD, respectively). The role of these
causes on the burden of liver disease
depends on disease severity and on geo-
graphical factors. In global north countries
such as France, fatty liver diseases (NAFLD,
ALD or its combination) account for most
cases of liver fibrosis while HBV is highly
prevalent in Asian countries.2 3 Regarding
advanced liver disease, ALD is the main
cause of cirrhosis worldwide, accounting for
50% of the cases.4 In Europe and the USA,
Strengths and limitations of this study
▪ This is the first comprehensive systematic study
assessing the relative attention to the major liver
diseases.
▪ This study develops a novel tool to estimate the
ratio between the research attention and burden
of major liver disease (ie, the Attention-to-
Burden Index or ABI).
▪ We found a strong correlation between the effi-
cacy of current pharmacological therapies and
the degree of research attention devoted to each
major liver disease, which strongly suggests the
need to reallocate more research resources to
alcoholic liver disease.
▪ The global burden of the major liver disease is
largely unknown and we used an array of differ-
ent variables.
▪ The efficacy of pharmacological therapies for
viral hepatitis can be easily calculated based on
viral parameters, while the parameters to evalu-
ate the resolution of fatty liver diseases are not
well established.
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stark increases in morbidity due to alcohol-associated
liver disease have been observed in the past 15 years.5 6
Importantly, the role of NAFLD as a cause of advanced
liver disease and hepatocellular carcinoma has markedly
increased in many countries due to the epidemics of dia-
betes and obesity.7
Major advances have been made in the management
of viral hepatitis, such as vaccines and oral therapies for
HBV, and oral regimes for HCV.8 9 In the past decade,
there has been an increased focus on NAFLD, with
studies identifying targeted therapies and subsequent
clinical trials.10 11 In comparison to the advances, ALD
has been afforded scant attention, with few advances in
its management.12 Patients with ALD are mostly identi-
fied at late stages of the disease, and programmes for
early detection are scarce. Moreover, the genetic and
environmental factors are largely unknown.
We hypothesised that differences in advancement
between viral hepatitis and fatty liver diseases, in particular
ALD, are related to varying allocations of research
resources. There are no systematic studies assessing the
relative research on different aetiologies of liver disease, or
how commensurate research attention is with disease
burden. The current study was undertaken to fill this gap.
METHODS
General design
For this systematic analysis, data on the research atten-
tion were obtained at multiple levels for the four main
liver disease aetiologies, carried out during the years
2010–2014, and analysed during 2015. The aetiologies
categorised were HCV, HBV, NAFLD and ALD, while
data on less prevalent liver diseases were considered but
not included in the final analysis. A quantitative scoring
system was used to define and subsequently measure
research attention to liver disease aetiology. When a
single cause of liver disease was identified in a presenta-
tion, grant, clinical trial or scientific publication, full
points (1.0 point) were allocated to the disease. When
two causes of liver disease were identified, points were
equally shared (0.5 point each). When the focus of a
study could be attributed to more than two causes of
liver disease or the study investigated a common mech-
anism (eg, hepatocellular apoptosis) and/or conse-
quence of liver diseases (eg, ascites), the finding was
excluded. Basic science studies that investigated
common mechanisms of liver disease were also
excluded.
Quantification of research attention
The relative level of attention to each liver disease was
calculated at five different levels: primary research pre-
sented at major scientific liver meetings, drugs in devel-
opment, research opportunities, clinical trials and
publications. The mean research attention was calcu-
lated by averaging the relative level of attention devoted
to each liver disease in each of the five categories.
Major scientific liver meetings
The scoring system for the two major global liver scien-
tific meetings (American Association Study of Liver
Diseases (AASLD) and European Association for the
Study of the Liver (EASL)) was designed to reflect the
quantity of presentations as well as the level of presenta-
tion. The scores were allocated as follows: 5 points, title
of a large symposium (eg, postgraduate course); 4 points,
title of small courses or joint workshops; 3 points, scien-
tific presentations at an oral general meeting or plenary
session, presidential lectures or state-of-the-art lectures
and titles of parallel session; 2 points, scientific presenta-
tions at a parallel session, early morning workshops,
meet-the-professor luncheon or grand rounds and titles
from sections of the poster presentations; and 1 point, sci-
entific presentation as a poster. The number of abstracts
in each category was multiplied by the allocated score to
provide an overall weighted research attention. Only clin-
ical and translational studies including human samples
were included. Scores for attention are reported as a per-
centage or total N.
Drugs in development
A systematic online search of the 38 major pharmaceut-
ical companies was made to determine the amount of
pharmacological therapies in development for the four
major liver diseases. Drugs in development that were
specifically indicated for one of the four liver diseases
were included in the analysis.
Research opportunities
The National Institutes of Health (NIH) Research
Portfolio Reporting Tools (RePORTER) was accessed to
identify public funding opportunities in the USA. The
following Boolean searches were performed using these
terms: ‘alcoholic liver disease’ excluding ‘non-alcoholic
fatty liver disease’, ‘hepatitis C virus’, ‘hepatitis B virus’,
‘nonalcoholic fatty liver disease’ excluding ‘alcoholic
liver disease’. To identify public grant opportunities for
the European Union (EU), the Community Research
and Development Information Service (CORDIS)
advanced search database was used, and the ‘Only
Projects’ tab was selected and the same search items
were entered. The number of corresponding grants was
recorded by disease category.
Clinical trials and scientific publications
The same search terms used for the research opportun-
ities section were entered into Clinicaltrials.gov and
PubMed to identify ongoing clinical trials and publica-
tions, respectively. Observational and interventional
ongoing studies for the four major liver diseases were
identified. Trials and/or publications on unspecific liver
diseases (ie, cirrhosis) were excluded.
Estimation of disease burden
We estimated the burden of each of the four main liver
diseases by combining parameters indicative of early and
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advanced liver disease as well as hospitalisation costs. The
following parameters were used to estimate the relative
burden of each of the major four liver diseases: (1) liver-
related mortality in the USA;13 (2) causes of liver fibrosis
estimated by non-invasive tests;14 (3) causes of liver cirrho-
sis;15 (4) cause of liver transplantation in the USA and
the EU. The causes of liver transplantation in Europe
were identified from the European Liver Transplantation
Registry. To account for patients with concurrent aetiolo-
gies (eg, HCV/ALD), we divided the number of patients
with HCV/ALD and assigned half of them to HCV and
half of them to ALD.16 17 (5) Inpatient hospitalisation
costs of patients with liver disease in the USA.18 (6)
Hospital admissions and discharges: the data were
obtained from the total number of patient discharges for
each of the four main liver diseases.18
Estimation of rate of efficacy of current pharmacological
therapies
We conducted a systematic review of the main controlled
clinical trials testing targeted therapies for viral hepatitis
and fatty liver diseases. Studies published during the
period 2010–2014 in the most cited journals were
included and reviewed. For HBV, the cure rate was deter-
mined by DNA clearance or persistent reduction of
Hepatitis B Surface Antigen (HBsAg). For HCV, we con-
sidered the sustained viral response (SVR) at 12 weeks to
help determine drug efficacies. In patients with biopsy-
proven non-alcoholic steatohepatitis (NASH), we defined
drug efficacy as histological improvement of patients in
the NAFLD Activity Score (NAS) score and/or fibrosis.
Regarding ALD, in the absence of consistent studies in
patients with early disease, rates of efficacy were based on
28-day survival in patients with alcoholic hepatitis (AH).
Development of the Attention-to-Burden Index
The Attention-to-Burden Index (ABI) was developed to
compare the research activities during 2010–2014, and
an estimate of disease burden of the four major liver dis-
eases. The ABI for each liver disease was calculated as
the mean research attention divided by the mean
disease burden for each liver disease. A resulting ratio
close to 1 reflects an appropriate attention compared
with the burden. In contrast, ABI reflects either overat-
tention (positive value) or inadequate attention (nega-
tive value) compared with the burden.
Statistical analysis
Descriptive data are reported for liver meeting attention,
drug development attention, published article attention,
clinical trial attention, research grant attention and
burden of disease as either N or per cent where appropri-
ate. Ratios were created comparing the proportion of
disease attention and proportion of disease burden. SPSS
software (Chapel Hill, North Carolina, USA) was used to
determine the Pearson’s correlation between drug efficacy
and research attention to the four main liver diseases. An
analysis of variance test was also carried out to determine
the level of significance of the correlation between
research attention and pharmaceutical drug efficacy.
RESULTS
Analysis of research attention to major liver diseases
(2010–2014)
We first performed a systematic analysis of the research
attention paid to the four main liver diseases during the
period 2010–2014 at five different levels. EASL meetings
had a research attention of 55% and 25% for HCV and
HBV, respectively, while NAFLD and ALD received 13% and
7%, respectively. AASLD meetings provided similar research
focus to HCV and HBV (attentions of 49% and 32%,
respectively) while NAFLD and ALD received 14% and 4%
(figure 1A, table 1 and online supplementary table S1).
In the analysis of drugs in the pipeline from the main
38 drug companies, we found 74 drugs specifically indi-
cated to treat these four major liver diseases. Eighty-two
per cent of such drugs were for HCV, mainly oral-acting
interferon-free regimes. A smaller proportion of drugs
were devoted to HBV (12%), while only 6% of the drugs
in development were focused on treating either NAFLD
(3%) or ALD (3%; see online supplementary table S2).
Next, research opportunities were assessed in public
agencies in the USA and the EU (see online
supplementary table S3). In the USA and the EU, it was
found that the majority of funding opportunities were
devoted to HCV (48% and 61%, respectively), followed
by HBV (21% and 30%; figure 1B). In contrast, NAFLD
received less attention (20% in the USA and 7% in the
EU) while ALD received minimal funding opportunities
(3% in the USA and 0% in the EU). Next, registered
clinical trials were analysed to determine the proportion
of focus devoted to the four main liver diseases. A total
of 1273 clinical trials were found, and most studies were
devoted to test anti-HCV and HBV drugs (32% and
36%, respectively; figure 1C). The proportion of
ongoing trials for NAFLD was 5%, while 18% of
ongoing trials were specifically devoted to ALD (table
2). These differences were similar when the clinical
trials were divided between interventional and observa-
tional trials (data not shown). Finally, the relative
number of scientific publications devoted to different
types of liver diseases was analysed for the period 2010–
2014. A total of 39 093 publications were found on the
four main liver diseases included in our study. Published
studies for HCV and HBV accounted for 46% and 32%,
respectively (figure 1D). The publications for NAFLD
were lower at 17%, and for ALD, even more so at 5%.
Overall, the mean research attention afforded to the
four main liver diseases was greater for HCV and HBV at
47% and 31%, respectively, than it was for NAFLD and
ALD at 17% and 5%, respectively (figure 2).
Estimation of disease burden for the major liver diseases
In the absence of systematic studies assessing the burden
of the major liver disease worldwide, we next estimated
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the overall burden of the four major liver diseases by
combining data from six different parameters (see
methods). The relative numbers of mortality caused by
liver disease in the USA can be attributed to 23% HCV,
0.54% to HBV, 3% to NAFLD and 50% to ALD.13 The
indications of liver fibrosis in the USA were 10% to
HCV, 7% to HBV, 48% to NAFLD and 35% to ALD.14
The causes of liver cirrhosis in the USA were 47% to
HCV, 3% to HBV, 27% to NAFLD and 25% to ALD.15
The main indications of liver transplantation in the EU
and the USA were attributed as 28% and 40% to HCV,
11% HBV (EU), in the USA there were no data on HBV
due to its low indication rate for transplantation, 10%
and 16% to NAFLD, and 39% and 23% to ALD.16 17
HCV and HBV contributed to $167 785 million (15%)
and $52 062 (5%) of hospitalisation costs, while NAFLD
and ALD contributed to $45 755 (4%) and $848 189
(76%), respectively, in the USA.18 The relative number
of hospital admissions and discharges were obtained
from Peery et al’s18 calculation of the burden of gastro-
intestinal disease in the USA in 2012, and were attribu-
ted to the four aetiologies of liver disease: at 14 749
(17%) and 4568 (5%) to HCV and HBV, and at 2858
(3%) and 64 752 (74%) to NAFLD and ALD (see online
Figure 1 Parameters of
research attention to the four
major liver diseases. The relative
level of attention devoted to each
liver disease from different
parameters: (A) detailed analysis
of all presentations at the two
major annual scientific liver
meetings (AASLD and EASL); (B)
research opportunities offered by
public agencies in the USA and in
the EU; (C) ongoing registered
clinical trials (ClinicalTrials.gov);
(D) scientific publications
(PubMed). AASLD, American
Association Study of Liver
Diseases; AH, alcoholic hepatitis;
ALD, alcoholic liver disease;
EASL, European Association for
the Study of the Liver; EU,
European Union; HBV, hepatitis B
virus; HCV, hepatitis C virus;
NAFLD, non-alcoholic fatty liver
disease; NASH, non-alcoholic
steatohepatitis; NIH, National
Institutes of Health.
Table 1 Weighted research attention to main liver diseases in the two most attended international liver conferences, 2010–
2014
Weighted values
2010–2014 HCV HBV NAFLD ALD
International Liver Conference EASL AASLD EASL AASLD EASL AASLD EASL AASLD
Symposia* 277.5 47.5 92.5 49.5 35 10 25 15
Titles of sessions† 144 278 100 164 50 110 42 44
Oral—general presentations‡ 78 43.5 21 13.5 27 6 3 3
Oral—parallel presentations§ 33 54 26 39 13 20 11 16
Poster presentation¶ 945.5 1708 423.5 1135 231 475.5 98.5 135
Total weighted points 1478 2131 663 1401 356 621.5 179.5 213
*Incidence multiplied by 5 research points. It includes courses, joint workshops and industry-supported satellite symposia.
†Incidence multiplied by 4 research points. It includes titles of entire oral parallel session and poster categories.
‡Incidence multiplied by 3 research points. It includes plenary sessions, presidential lectures, state-of-the-art lectures and European Liver
Patients Association (ELPA) workshops.
§Incidence multiplied by 2 research points. It includes early morning workshops, meet-the-professor luncheons and grand rounds.
¶Incidence multiplied by 1 research point.
AASLD, American Association for the Study of the Liver; ALD, alcoholic liver disease; EASL, European Association for the Study of Liver
Diseases; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease.
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supplementary table S4). Taking into account all these
parameters, the mean disease burden was calculated at
28% and 5% for HCV and HBV, respectively, and 17%
and 50% for NAFLD and ALD (figure 3).
Relative research attention compared with disease burden
(ABI)
In order to critically analyse if there are disparities
between the attention that the liver research community
pays to the major liver disease and their burden, we gen-
erated ABI (if the relative attention equals the relative
burden of a given liver disease, the ratio should be 1).
The calculated ABI for hepatitis B and C revealed a
+6.7-fold and +1.7-fold overattention, respectively.
NAFLD received an ABI of −1.2-fold, reflecting its
recent rise in attention within the field of hepatology,
while ALD received a marked inadequate attention of
−9.7-fold (figure 4 and table 3). The ABI indicates that
while viral hepatitis has been extensively studied during
the past years, ALD is being markedly overlooked.
Efficacy rate of current therapies: correlation with the
degree of research attention
Finally, we hypothesised that there is a relationship
between the degree of research attention to each major
liver disease and the therapeutic advances. In order to
address this question, we conducted a systematic review
of the main controlled clinical trials testing targeted
therapies for viral hepatitis and fatty liver diseases. For
HBV and HCV, we determined the efficacy in terms of
sustained viral response. In patients with biopsy-proven
NASH, we defined drug efficacy as histological improve-
ment of patients in the NAS and/or fibrosis. Regarding
ALD, there are no consistent clinical trials to test tar-
geted therapies in patients with early/compensated
forms. Therefore, we focus on the efficacy of drugs in
improving short-term survival in patients with AH.
Following these criteria, the efficacy rate of current
pharmacological agents was 72% for HBV, 89% for HCV,
25% for NASH and 13% for AH (figure 5A and see
online supplementary table S5). Importantly, there was a
positive relationship between the mean attention to
each major liver disease and the success rate of pharma-
cological therapies (figure 5B). This figure strongly sug-
gests that the greater the concentration of research on
one liver disease, the more likely to develop efficacious
drugs.18–46
DISCUSSION
In the past decade, major advances have been achieved
in the field of viral hepatitis, with the development of
highly active oral antiviral therapies. In clear contrast,
there are no approved therapies for NAFLD and ALD
Table 2 Research attention from clinical trials, public agencies and PubMed
HCV (n, %) HBV NAFLD ALD
Drugs in development 61 (82) 9 (12) 2 (3) 2 (3)
EASL 1478 (55) 663 (25) 356 (13) 179.5 (7)
AASLD 2131 (49) 1401 (32) 621.5 (14) 135 (5)
PubMed 15 438 (39) 10 724 (27) 5518 (14) 1728 (4)
NIH grants 738 (48) 328 (21) 300 (20) 47 (3)
EU grants 52.5 (61) 25.5 (30) 6 (7) 0 (0)
Clinical trials 407 (32) 461 (36) 66 (5) 235 (18)
Mean research attention 47% 31% 17% 5%
Percentages in parentheses calculated from a combination of HCV, HBV, NAFLD and ALD.
AASLD, American Association for the Study of the Liver; ALD, alcoholic liver disease; EASL, European Association for the Study of Liver
Diseases; EU, European Union; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; NIH, National
Institutes of Health.
Figure 2 Calculation of mean research attention to the four
major liver diseases. The mean research attention to the four
main liver diseases (HBV, HCV, NAFLD and ALD) was
calculated from five parameters: scientific publications
(PubMed); research opportunities offered by public agencies
in the USA and the EU; ongoing registered clinical trials
(ClinicalTrials.gov); detailed analysis of all presentations at the
two major annual scientific liver meetings (AASLD and EASL);
and number of drugs in development in the pipeline of 38
major pharmaceutical companies. AASLD, American
Association Study of Liver Diseases; ALD, alcoholic liver
disease; EASL, European Association for the Study of the
Liver; EU, European Union; HBV, hepatitis B virus; HCV,
hepatitis C virus; NAFLD, non-alcoholic fatty liver disease.
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and interventions for AH are largely unchanged over
the past 40+ years. We hypothesised that these discrep-
ant advances are related to unequal allocation of
research resources. Our systematic study found marked
disparities between research attention and disease
burden among the aetiologies of liver disease. We com-
pared multiple modalities of hepatology research atten-
tion (eg, scientific meeting presentations, research
funding, drugs under development, funding opportun-
ities and publications) with measures of liver disease
burden (prevalence, fibrosis and healthcare costs). We
found a lack of correlation between research attention
and disease burden. Overall, viral hepatitis received a
5–7-fold overattention, while alcoholic liver disease
received a 10-fold underattention. There are a few
similar studies in other fields of medicine that have
investigated research attention and disease burden.47
Using a similar methodology to ours, these studies used
clinicaltrials.gov, while others compared NIH funding
to disease burden. Unfortunately, the discrepancy
between funding and burden has become a common
theme.
The finding of attention–burden discordance is most
likely multifactorial. HBV and HCV are causes of cirrho-
sis and hepatocellular carcinoma, and are important
public health issues in their own right.1 2 Therapeutic
targets for viral hepatitis are better defined than those
for fatty liver diseases (eg, proteins regulating viral repli-
cation), and there is a significant interest to develop
antiviral agents. It is important to recognise that the
nature of these diseases also plays an important role in
the development of drug therapies. The pathways of
viral hepatitis (HBV and HCV) diseases have a signifi-
cant positive effect on the advancement of effective
drug therapies compared with that of fatty liver diseases.
HBV and HCV have clear aetiologies, with transmission
of the virus occurring in determined pathways which
provide scientific researchers with clear targets for the
development of pharmacotherapies. In contrast, fatty
liver diseases (NAFLD and ALD) have multiple causes
and are linked to other health conditions, their complex
aetiologies, which necessitate the development of ther-
apies that address multiple targets, and may contribute
to the lack of drugs targeted to NAFLD or ALD.
Figure 3 Estimation of mean
disease burden to four main liver
diseases. The mean disease
burden to the four main liver
diseases (HBV, HCV, NAFLD and
ALD) was calculated from seven
parameters: total number of US
hospitals discharged, US
hospitalisation costs, OLTY-EU,
OLTY-US, cirrhosis-US, fibrosis
and US mortality. ALD, alcoholic
liver disease; HBV, hepatitis B
virus; HCV, hepatitis C virus;
NAFLD, non-alcoholic fatty liver
disease.
Figure 4 ABI for the four major
liver diseases. ABI was calculated
using the ratio of mean research
attention (comprising different
parameters shown in figure 1) to
mean disease burden (comprising
the parameters shown in figure 2)
of the four main liver diseases. A
value >1 reflects overattention
compared with the disease
burden, while a value <1 reflects
inadequate attention. ABI,
Attention-to-Burden Index ALD,
alcoholic liver disease; HBV,
hepatitis B virus; HCV, hepatitis C
virus; NAFLD, non-alcoholic fatty
liver disease.
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It is observed that increases in attention become self-
perpetuating, with scientific advances (ie, drug develop-
ment efforts, research allotment, etc) influencing greater
research attention (more presentations, drugs, funding
opportunities and publications) and vice versa. The inad-
equate attention especially to ALD is complex and
includes the social stigma surrounding alcoholism, poorly
defined targets for therapy, a lack of good animal models,
few non-invasive markers of severity and poor general
awareness of the diseases. Additionally, there is a lack of
large-scale early detection efforts, and thus patients are
often identified at very late stages of the disease. These
challenges alongside patient identification, research and
therapy result in a high burden of disease.
Our findings should be viewed as a comparative assess-
ment of relative attention and burden among the major
liver diseases. While we completed an extensive search,
which expanded over a 5-year period and involved mul-
tiple areas within both the public and private sectors,
our estimates were derived from pre-existing databases
with their own respective inclusion and exclusion cri-
teria. Thus, limitations of this study include the possibil-
ity of incomplete estimates. Other limitations include
the inability to complete a systematic review of the
global burden of the major liver diseases due to the
limited number of articles that focus on fatty liver
disease burdens. The limited and heterogeneous
resources used for burden estimates reflect the need for
further research.
Consequences of this large discrepancy among hepa-
titis and fatty liver diseases include extraordinary
advances in the therapy of HCV and HBV prevention,
while little advancements in early detection and treat-
ment of ALD and NAFLD have been made. It is
unknown if these differences impact mortality. The next
decade could benefit from greater research attention
being allocated to NAFLD and ALD. Translational
studies identifying targets for therapy for fatty liver
disease will certainly encourage pharmaceutical compan-
ies to invest in clinical trials. Ultimately, efforts by public
funding agencies and the scientific community to
address the diseases with the greatest public health
burden will result in improved health outcomes for the
greatest number of people.
A striking finding of our study is the minimal attention
that both public and private sources pay to ALD, which
is the main cause of cirrhosis globally.4 In recent years, a
concurrent increase in addiction behaviour and the
prevalence of resulting illnesses such as ALD has been
observed in the USA and Europe.5 6 Accompanying the
sharp rise in ALD cases is the increasing burden of
patients with liver disease on national health systems,
identifying them as the main group expenditures in
patient hospitalisation costs.18 In spite of its significant
health and socioeconomic burden, few major advances
have been made in the management of patients with
ALD. The pharmacological therapies used today have
not changed since 1971 (ie, prednisolone for AH), and
no widespread early detection programmes have been
developed.48 Our study should increase awareness in the
public health agencies and academic institutions, espe-
cially in Europe, to devote more resources to face this
Table 3 Attention to Burden Index
HBV HCV NAFLD ALD
Mean research attention 29% 51% 15% 5%
Mean disease burden 5% 28% 17% 50%
Ratio 6.71 1.67 0.93 0.10
Fold-over ratio 6.71 1.67 −1.08 −9.68
Attention-to-Burden Score 6.71 1.7 −1.1 −9.7
The Attention-to-Burden score is bolded to highlight it. It is the
final score that was calculated that informed the Attention Burden
Index.
ALD, alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis
C virus; NAFLD, non-alcoholic fatty liver disease.
Figure 5 Correlation between the efficacy of current drug therapies for hepatitis and the mean research attention. (A) Current
mean rate of efficacy for therapeutic drugs; (B) correlation between the efficacy of current drug therapies for hepatitis and the
mean research attention. The efficacy of current drug therapies to treat chronic hepatitis (HCV), chronic hepatitis B (HBV), NASH
and AH was calculated based on large published clinical trials (see Methods section). Definition criteria of drug efficacy for each
of the four type of hepatitis were: HCV: sustained viral response at 12 weeks; HBV: achievement of end points suppressing viral
replication; NASH: reduction in NAS or fibrosis score; AH: effect on short-term mortality rate. AH, alcoholic hepatitis; HBV,
hepatitis B virus; HCV, hepatitis C virus; NAS, NAFLD Activity Score; NASH, non-alcoholic steatohepatitis.
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prevalent and devastating liver disease. The develop-
ment of a European Agency for Alcohol Studies, similar
to the National Institute for Alcohol and Alcoholism
(NIAAA) in the USA, seems a timely initiative.
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